The quarter modestly beat the published loss expectation. Analysts were looking for roughly $(1.63) per share, versus the reported $(1.50), although no dependable published revenue estimate is available here. The more important operating datapoint was MYQORZO net product revenue of $25.3 million, including $23.0 million from the U.S. and $2.3 million of initial German distributor inventory (Revenues).
| $ millions, except per-share data | Q2 2026 | Q2 2025 / expectation |
|---|---|---|
| Total revenue | $28.6 | $66.8 |
| MYQORZO net product revenue | $25.3 | — |
| Collaboration revenue | $3.3 | $2.4 |
| Net loss | $(198.8) | $(134.4) |
| Loss per share | $(1.50) | $(1.12) / consensus ~$(1.63) |
| R&D expense | $97.8 | $110.1 |
| SG&A expense | $104.4 | $65.7 |
| Cash, cash equivalents and investments | $1.7 billion | $1.1 billion at March 31, 2026 |
Commercial traction is arriving faster than the headline revenue comparison suggests. U.S. product revenue increased sharply from $4.8 million in Q1, while more than 700 providers prescribed MYQORZO, approximately 1,500 patients received product, and over 80% of patients on therapy had paid prescriptions (Q2 Commercial Update). The German contribution was partly channel inventory rather than fully realized patient demand, so the underlying launch signal is encouraging but not yet a clean measure of recurring international sales.
ACACIA-HCM materially expands the opportunity, but its risk profile remains visible. The trial met both primary endpoints and supported the planned supplemental filing for non-obstructive HCM in Q4 2026 (Cardiac Muscle Programs). However, reduced LVEF below 50% occurred in 10% of aficamten patients versus 1% on placebo, with two serious heart-failure events associated with reduced LVEF (ACACIA-HCM Safety Results). The positive efficacy result is therefore meaningful, but the full dataset and regulatory interpretation still matter.
The trade-off is higher spending and shareholder dilution to fund the expansion. Full-year combined R&D and SG&A guidance rose from $830–$870 million to $860–$890 million, explicitly reflecting commercial-readiness spending for a potential 2027 non-obstructive HCM launch (2026 Financial Guidance). Cash rose to approximately $1.7 billion after a $760.1 million equity offering at $71 per share, strengthening funding capacity but increasing the share count by 11.3 million shares (Cash, Cash Equivalents and Investments; Balance Sheets). Net versus expectations, the modest EPS beat and stronger launch/pipeline picture outweigh the higher cost base, but the result is not an unqualified positive because commercialization still requires substantial investment and ACACIA carries a safety issue regulators will scrutinize.
Read the original 8-K on SEC EDGAR ↗